Since the agreement by the G20 group of the worldâ€™s leading economies in 2009 to implement substantial reforms to the regulations governing OTC derivatives markets, financial institutions, end users and other market participants have started to prepare for the wide ranging implications of such changes, in readiness for the end-2012 deadline. To date, legislation has been enabled for a substantial overhaul of regulations governing the global OTC derivatives marketplace. The United States has been in the forefront of this, with the Dodd-Frank Act passed in 2010, whilst EU initiatives, via European Market Infrastructure Regulations (EMIR) and revisions to MIFID following. Both sets of regulations are leading to a substantial number of new rules, the details of which in part remain in flux, the establishment of new regulatory bodies, and a significant increase in the regulatory burden for market participants with wide ranging impact from front to back office. In particular, concerns remain regarding the duplication of regulations, extraterritorial jurisdiction and the possibility of regulatory arbitrage as different countries introduce different regulatory standards. This programme seeks to provide participants with a comprehensive guide to the structure of the regulatory reforms in both legislative regimes, with respect to trading environments, clearing and reporting of OTC derivatives, margin collateral, capital requirements, disclosure and governance. The agenda will examine the scope of the regulations, by product and depending on the classification of market participants, and evaluate some of the implications for market makers, corporate and institutional end users, as well as some of the current concerns within the industry as the extensive new rules are in the process of being finalised.